Veritas In Silico Inc.(130A) News

Announcement of the Publication of a Research Article on AISLAR, a Method for Streamlining Screening That Supports Our AI-Driven Drug Discovery

Veritas In Silico tumbles for first time in 3 sessions after ending joint drug discovery research with Takeda◇

Termination of Collaborative Drug Discovery Research with Takeda on mRNA-Targeted Small-Molecule Drugs

Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member

Veritas In Silico, The Current Fiscal Year's Net Income to Widen

Financial Results - Fiscal Year Ended December 31, 2025

Company Presentation

Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP]

SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter

The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS

Upgrading the Drug Discovery Platform ibVIS to aibVIS

Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline

Company Presentation

Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio"

Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction

Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP]

Veritas In Silico, Jan-Sep (Cumulative 3Q) Ordinary Profit Loss Widens, Jul-Sep Ordinary Profit Loss Widens

Financial Results - Fiscal Year Ending December 2025, 3rd Quarter　

Organizational Reforms and Personnel Changes

[Summary] Financial Results for the Nine Months